MAPK14 and acute myeloid leukemia: Our present study also showed that a p38 inhibitor reversed the EF-24 (2 μM)-induced activation of PP2A, suggesting that EF-24 might activate p38 to upregulate PP2A activity and further deactivate ERK in HL-60 AML cells.